Molecular Tumor Board 2021-22

Thoracic Tumor - Somatic and germinal deletions are explored in this module, offering insights into the clinical impact of these deletions in thoracic tumors, presented by Dr. Lucio Ghiglione.

Learning from failures is the focus of this module, presented by Dr. Helena Oliveres. Participants will gain valuable insights into learning from unsuccessful cases in the context of tumor molecular profiles.

This module, led by Dr. Lydia Gaba, delves into the identification of patients for PARPis in Ovarian Cancer. Participants will explore the best practices for identifying suitable patients for this treatment.

Dr. Francesco Schettini leads this module, providing an in-depth understanding of therapeutic decision-making in HR+HER2-negative Metastatic Breast Cancer based on intrinsic subtypes.

Exploring DNA repair and the clinical evolution of metastatic prostate cancer, this module, led by Dr. Caterina Aversa, offers insights into the evolving landscape of treatment strategies.

Dr. Barbara Adamo presents a module focusing on a change in phenotype and somatic BRCA1 mutation in a patient with advanced breast cancer, shedding light on the clinical implications of these changes.

Done right, went wrong is the theme of this module, led by Dr. Victor Albarran. Participants will gain valuable insights into cases where the initial approach did not yield the expected results.

Can a treatment strategy be guided without a somatic molecular profile? This module, presented by Dr. Juan Carlos Laguna, addresses this important question, offering practical insights into treatment decision-making.

This module, led by Dr. Elia Segui, delves into precision medicine in non-melanoma skin cancer, offering a comprehensive understanding of tailored treatment strategies for this specific cancer type.

Dr. David Pesantez presents a module focused on unexpected responses in rare tumors, providing valuable insights into the challenges and opportunities in managing such cases.

Improving survival in metastatic breast cancer is the central theme of this module, presented by Dr. Maria Vidal, offering practical strategies to enhance patient outcomes in this context.

Beyond BRCA1 and 2 in ovarian cancer is explored in this module, led by Dr. Adela Rodríguez, providing insights into the evolving landscape of precision medicine in ovarian cancer.

This module, presented by Dr. Belen Pastor, focuses on the correct interpretation of tumor molecular studies and the importance of a multidisciplinary approach, shedding light on the critical role of accurate interpretation in clinical decision-making.

Never too late to think twice is the theme of this module, led by Dr. Marta García de Herreros, offering insights into cases where re-evaluation and reconsideration are crucial for optimal patient management.

Exploring predictive biomarkers in urothelial carcinoma (UC) beyond FGFR alterations, this module, led by Dr. Oscar Reig, offers valuable insights into identifying predictive markers for tailored treatment approaches.

Dr. Laura Angelats presents a module on agnostic biomarkers in solid tumors, providing insights into the evolving landscape of identifying and utilizing biomarkers in various solid tumor types.

What acral melanoma hides is the focus of this module, led by Dr. Roberto Martín, offering valuable insights into understanding the complexities associated with acral melanoma and its clinical implications.

Dr. Roxana Reyes leads this module, exploring the concept of molecular family in the context of tumor molecular profiling, shedding light on the interconnectedness of molecular profiles within families of tumors.

Is there a role for precision medicine in rare pancreatic cancer? This module, presented by Dr. Francis Espósito, delves into the challenges and opportunities in tailoring treatment strategies for rare pancreatic cancer cases.

Beyond the classical EGFR resistance mechanisms is the focus of this module, led by Teresa Gorria, offering insights into the evolving understanding of resistance mechanisms in EGFR-mutated tumors.

Exploring breast cancer beyond intrinsic subtypes is the theme of this module, presented by Raquel Gómez, offering a comprehensive understanding of the diverse molecular landscape in breast cancer beyond traditional subtypes.

Dr. Iván Victoria leads this module, delving into treatment strategies beyond chemotherapy in intrahepatic cholangiocarcinoma, offering insights into personalized treatment approaches for this specific cancer type.

Exploiting genomics in serous endometrial cancer is the theme of this module, led by Lydia Gaba, providing valuable insights into the evolving role of genomics in the management of serous endometrial cancer cases.

Beyond classical BRAF mutations in melanoma is explored in this module, led by Dr. Marta García de Herreros, offering insights into the complexities and opportunities beyond traditional molecular markers in melanoma.

Can precision immuno-oncology be applied in HR+ HER2- Breast Cancer? This module, presented by Elia Seguí, delves into the potential role of precision immuno-oncology in the context of HR+ HER2- Breast Cancer.

Estela Pineda presents a module focused on brain tumors, offering insights into the evolving landscape of understanding and managing brain tumors based on molecular profiles.